A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry
Authors:
- Ayşe CefleACAyşe Cefle
- Nurullah AkkoçNANurullah Akkoç
- Haner DireskeneliHDHaner Direskeneli
- Fatih YıldızFYFatih Yıldız
- Gözde Yildirim ÇetinGÇGözde Yildirim Çetin
- Şule YavuzŞYŞule Yavuz
- Seminur HaznedaroğluSHSeminur Haznedaroğlu
- Berna GökerBGBerna Göker
- Özgül Soysal GündüzÖGÖzgül Soysal Gündüz
- Cemal BesCBCemal Bes
- Şükran ErtenŞEŞükran Erten
- Neslihan YılmazNYNeslihan Yılmaz
Open Access
- 14 March 2022
- journal article
- research article
- Published by AVES YAYINCILIK A.Ş. in European Journal of Rheumatology
- Vol. 9 (2) , 82-87
Abstract
Objective: TURKBIO registry, established in 2011, is the first nationwide biological database in Turkey. This study aimed to provide an overview of TURKBIO data collected by June 2018. Methods: The registry included adult patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), nonradiographic axial spondyloarthritis (nr-AxSpA), and psoriatic arthritis (PsA). Demographic and clinical features, disease activity markers, and other follow-up parameters, current and previous treat- ments, and adverse events were registered electronically at each visit using open-source software. The registration of patient-reported outcome measures was carried out electronically by the patients using touch screens. Results: TURKBIO registry included a total of 41,145 treatment series with biologicals. There were 2,588 patients with axSpA (2,459 AS and 129 nr-axSpA), 2,036 with RA, and 428 with PsA. The total number of patients, including those with other diagnoses, was 5,718. In the follow-up period, the number of patients and also visits steadily increased by years. The yearly mean number of visits per patient was found to be 2.3. Significant improvements in disease activity and health assessment parameters were observed following the biological treatments. Biologics were often given in combination with a con- ventional synthetic disease-modifying antirheumatic drug in patients with RA. Infections were the most commonly seen adverse events, followed by allergic reactions. Tuberculosis was observed in 12 patients, malignancy in 18, and treatment-related mortality in 31. Conclusion: TURKBIO provided a valuable real-life experience with the use of biologics in rheumatic diseases in Turkey. Cite this article as: O€ nen F, Can G, C apar S, et al. A real-life analysis of patients with rheumatologic diseases on biological treatments: Data from TURKBIO Registry.Eur J Rheumatol. 2022;9(2):82-87.Keywords
This publication has 10 references indexed in Scilit:
- Drug retention, inactive disease and response rates in 1860 patients with axial spondyloarthritis initiating secukinumab treatment: routine care data from 13 registries in the EuroSpA collaborationRMD Open, 2020
- Treatment response and drug retention rates in 24 195 biologic-naïve patients with axial spondyloarthritis initiating TNFi treatment: routine care data from 12 registries in the EuroSpA collaborationAnnals of the Rheumatic Diseases, 2019
- Retention and response rates in 14 261 PsA patients starting TNF inhibitor treatment—results from 12 countries in EuroSpARheumatology, 2019
- Effect of tight control of inflammation in early psoriatic arthritis (TICOPA): a UK multicentre, open-label, randomised controlled trialThe Lancet, 2015
- Prevalence of Inflammatory Back Pain and Axial Spondyloarthritis Among University Employees in Izmir, TurkeyThe Journal of Rheumatology, 2015
- Prevalence of ankylosing spondylitis and related spondyloarthritides in an urban area of Izmir, Turkey.2007
- A Norwegian DMARD register: prescriptions of DMARDs and biological agents to patients with inflammatory rheumatic diseases.2005
- DANBIO: a nationwide registry of biological therapies in Denmark.2005
- The prevalence of rheumatoid arthritis in an urban population of Izmir-Turkey.2004
- Effect of a treatment strategy of tight control for rheumatoid arthritis (the TICORA study): a single-blind randomised controlled trialThe Lancet, 2004